Undisclosed Pharma Contributions
Most health advocacy organizations do not report industry funding.
In 2007, Eli Lilly and Company gave the National Alliance on Mental Illness (NAMI) $450,000 toward its Campaign for the Mind of America, which, if successful, could greatly expand the market for Lilly’s newest and most expensive psychiatric drugs.
Potential conflict of interest in the funding of health advocacy organizations (HAOs) by pharmaceutical companies is hard to suss out, because those relationships are mostly not made public. After doing a systematic analysis of the disclosure...
Want more? Sorry, the full text of this article is only available to subscribers. Subscribe now.
Already a subscriber? Please log in by entering your email address and password into the red login box at the top-right corner of this page.
Need to register for your premium online access, which is included with your paid subscription? Register here.
How detention and deportation policies harm the health and well-being of children and families.
If we want to develop a new industry, alignment of interests is critical for long-term success.
Health systems need to rethink their programs to take full advantage of health reform—and reframe their value to the communities they serve.
Research shows that healthcare social enterprises are segmenting the BOP and leaving the bottom 50 percent of consumers behind.
Solnechny Mir (Our Sunny World) is a Russian rehabilitation center that hosts more than 250 children and their families each week.
A community-based program in rural Kentucky uses face-to-face social networks to promote wellness.
The knowledge, skill, and compassion of the health care community can help stop modern slavery.
Getting promising drug discoveries out of university labs and into the drug pipeline is more difficult than it should be.
Advance market commitments can help solve global development problems impaired by market failure.
